Tryptamine Therapeutics (AU:TYP) has released an update.
Don't Miss Our Christmas Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Tryptamine Therapeutics has announced the successful and safe administration of its innovative psilocin-based IV infusion, TRP-8803, to the first obese participant in a Phase 1b study. This trial, conducted in Adelaide, aims to optimize dosing rates and gather valuable data for future Phase 2 trials targeting weight-related conditions. With additional participants to be dosed soon, the company expects interim results later this year.
For further insights into AU:TYP stock, check out TipRanks’ Stock Analysis page.